Patients must be at least 18 years old and meet one of the following clinical requirements when GLP-1 therapy begins: A body mass index, or BMI, of 35 or higher A BMI between 30 and 34.99 with at least one qualifying health condition A BMI between 27 and 29.99 with at least one qualifying higher-risk health condition For someone with a BMI between 30 and 34.99, qualifying conditions may include heart failure with preserved ejection fraction, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
GHS-R1a engagement initiates Gq/G11-mediated PLC activation, producing inositol 1,4,5-trisphosphate (IP) and mobilizing intracellular calcium stores, culminating in GH vesicle exocytosis
Weighted vest use or resistance exercise to offset weight loss-associated bone loss in older adults: a randomized clinical trial
Product launches come with a point of view
A novel hypromellose capsule, with acid-resistance properties, permits the targeted delivery of acid-sensitive products to the intestine
Legal Recourse : Patients can file personal injury lawsuits or join class action suits against drug manufacturers, distributors, and healthcare providers who failed to ensure the safety of the medication
